• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Influence of intestinal efflux pumps on the absorption and transport of furosemide.肠外排泵对呋塞米吸收和转运的影响。
Saudi Pharm J. 2010 Apr;18(2):97-101. doi: 10.1016/j.jsps.2010.02.005. Epub 2010 Feb 13.
2
The effects of PLGA microparticles on intestinal absorption of p-glycoprotein substrate using the everted rat intestinal sac model.PLGA 微球对外翻肠囊模型中 P-糖蛋白底物肠吸收的影响。
Arch Pharm Res. 2011 Nov;34(11):1989-97. doi: 10.1007/s12272-011-1120-1. Epub 2011 Dec 3.
3
pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ.P-糖蛋白在限制质子化药物肠道吸收中的pH依赖性功能活性:奎尼丁原位外排的动力学分析
J Pharm Sci. 2005 Dec;94(12):2632-43. doi: 10.1002/jps.20489.
4
The application of P-gp inhibiting phospholipids as novel oral bioavailability enhancers - An in vitro and in vivo comparison.P-糖蛋白抑制性磷脂作为新型口服生物利用度增强剂的应用——体外和体内比较
Eur J Pharm Sci. 2017 Oct 15;108:13-22. doi: 10.1016/j.ejps.2016.08.055. Epub 2016 Aug 30.
5
Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.通过辅料抑制肠道外源性物质流出转运体——乳腺癌耐药蛋白,提高拓扑替康的口服药物吸收。
Drug Metab Dispos. 2007 Jul;35(7):1142-8. doi: 10.1124/dmd.106.014217. Epub 2007 Apr 19.
6
Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion.辅料通过抑制 P-糖蛋白增强更昔洛韦的肠道吸收:通过外翻肠囊和改良肠灌流在体评估。
Int J Pharm. 2011 Jan 17;403(1-2):37-45. doi: 10.1016/j.ijpharm.2010.10.017. Epub 2010 Oct 20.
7
An Investigation into the Role of P-Glycoprotein in the Intestinal Absorption of Repaglinide: Assessed by Everted Gut Sac and Caco-2 Cell Line.P-糖蛋白在瑞格列奈肠道吸收中作用的研究:通过外翻肠囊和Caco-2细胞系进行评估
Iran J Pharm Res. 2019 Winter;18(1):102-110.
8
Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies.增强P-糖蛋白(P-gp)底物药物肠道转运与吸收的脂质制剂策略:体外/体内案例研究
J Pharm Sci. 2007 Feb;96(2):235-48. doi: 10.1002/jps.20780.
9
Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.药物辅料的亲水亲油平衡值与其在Caco-2细胞和大鼠肠道中的多药耐药调节作用之间的关系。
J Control Release. 2003 Jun 5;90(1):37-48. doi: 10.1016/s0168-3659(03)00163-9.
10
Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes.采用离体大鼠肠膜,通过体外扩散室法研究聚氧乙烯蓖麻油(Cremophor EL)和其他表面活性剂对肠道P-糖蛋白功能的调节作用。
J Pharm Sci. 2004 Apr;93(4):877-85. doi: 10.1002/jps.20017.

引用本文的文献

1
Maximum likelihood estimation of renal transporter ontogeny profiles for pediatric PBPK modeling.最大似然估计法用于儿科 PBPK 模型中肾转运体个体发育曲线的构建。
CPT Pharmacometrics Syst Pharmacol. 2024 Apr;13(4):576-588. doi: 10.1002/psp4.13102. Epub 2024 Jan 10.
2
A Study on Pharmacokinetic Functionalities and Safety Margins of an Optimized Simvastatin Nanoformulation.优化后的辛伐他汀纳米制剂的药代动力学特性及安全边际研究
Pharmaceuticals (Basel). 2023 Mar 1;16(3):380. doi: 10.3390/ph16030380.
3
Solid Self-Nano Emulsifying Nanoplatform Loaded with Tamoxifen and Resveratrol for Treatment of Breast Cancer.负载他莫昔芬和白藜芦醇的固体自纳米乳化纳米平台用于乳腺癌治疗
Pharmaceutics. 2022 Jul 18;14(7):1486. doi: 10.3390/pharmaceutics14071486.
4
Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide.摄取和外排转运体对呋塞米口服药代动力学的贡献。
ACS Omega. 2020 Dec 15;5(51):32939-32950. doi: 10.1021/acsomega.0c03930. eCollection 2020 Dec 29.
5
Paracellular Pathway Enhancement of Metformin Hydrochloride Molecular Dispersion in Span 60 Microparticles.盐酸二甲双胍分子分散体在司盘60微粒中的细胞旁途径增强作用
Front Pharmacol. 2019 Jul 18;10:713. doi: 10.3389/fphar.2019.00713. eCollection 2019.
6
Renal Drug Transporters and Drug Interactions.肾脏药物转运体与药物相互作用
Clin Pharmacokinet. 2017 Aug;56(8):825-892. doi: 10.1007/s40262-017-0506-8.
7
Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy.绕过P-糖蛋白药物外排机制:在耐药性精神分裂症治疗中的可能应用。
Biomed Res Int. 2015;2015:484963. doi: 10.1155/2015/484963. Epub 2015 Sep 27.
8
Applying Biopharmaceutical Classification System (BCS) Criteria to Predict Oral Absorption of Drugs in Dogs: Challenges and Pitfalls.应用生物药剂学分类系统(BCS)标准预测犬类药物的口服吸收:挑战与陷阱
AAPS J. 2015 Jul;17(4):948-64. doi: 10.1208/s12248-015-9743-7. Epub 2015 Apr 29.

本文引用的文献

1
Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies.采用反相液相色谱法同时测定拓扑替康和模型渗透性标记物(阿替洛尔、安替比林、普萘洛尔和呋塞米):在Caco-2细胞肠道吸收研究中的应用
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Nov 15;859(2):261-6. doi: 10.1016/j.jchromb.2007.09.025. Epub 2007 Nov 1.
2
Physical and biological considerations for the use of nonaqueous solvents in oral bioavailability enhancement.用于提高口服生物利用度的非水溶剂的物理和生物学考量。
J Pharm Sci. 2008 Mar;97(3):1071-88. doi: 10.1002/jps.21060.
3
pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ.P-糖蛋白在限制质子化药物肠道吸收中的pH依赖性功能活性:奎尼丁原位外排的动力学分析
J Pharm Sci. 2005 Dec;94(12):2632-43. doi: 10.1002/jps.20489.
4
Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability.基于大鼠原位通透性对P-糖蛋白抑制作用下体内肠道吸收增强的预测。
J Pharm Sci. 2005 Aug;94(8):1694-704. doi: 10.1002/jps.20309.
5
Simultaneous determination of digoxin and permeability markers in rat in situ intestinal perfusion samples by RP-HPLC.采用反相高效液相色谱法同时测定大鼠原位肠灌注样品中的地高辛和通透性标志物。
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Dec 25;813(1-2):347-52. doi: 10.1016/j.jchromb.2004.09.047.
6
Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.常用的表面活性剂吐温80可提高大鼠体内P-糖蛋白底物地高辛的吸收。
Arch Pharm Res. 2003 Sep;26(9):768-72. doi: 10.1007/BF02976689.
7
Relationships between the hydrophilic-lipophilic balance values of pharmaceutical excipients and their multidrug resistance modulating effect in Caco-2 cells and rat intestines.药物辅料的亲水亲油平衡值与其在Caco-2细胞和大鼠肠道中的多药耐药调节作用之间的关系。
J Control Release. 2003 Jun 5;90(1):37-48. doi: 10.1016/s0168-3659(03)00163-9.
8
In vitro and in vivo study in rats of rectal suppositories containing furosemide.含呋塞米直肠栓剂在大鼠体内外的研究
Eur J Pharm Biopharm. 2002 May;53(3):311-5. doi: 10.1016/s0939-6411(02)00005-x.
9
Effect of common excipients on Caco-2 transport of low-permeability drugs.常用辅料对低渗透性药物Caco-2细胞转运的影响。
J Pharm Sci. 2001 Nov;90(11):1776-86. doi: 10.1002/jps.1127.
10
Rational use of in vitro P-glycoprotein assays in drug discovery.体外P-糖蛋白测定在药物研发中的合理应用。
J Pharmacol Exp Ther. 2001 Nov;299(2):620-8.

肠外排泵对呋塞米吸收和转运的影响。

Influence of intestinal efflux pumps on the absorption and transport of furosemide.

机构信息

Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.

出版信息

Saudi Pharm J. 2010 Apr;18(2):97-101. doi: 10.1016/j.jsps.2010.02.005. Epub 2010 Feb 13.

DOI:10.1016/j.jsps.2010.02.005
PMID:23960725
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3730994/
Abstract

PURPOSE

Furosemide is a commonly used diuretic which is used in the treatment of edema, congestive heart failure, hypertension and renal failure. Its absorption exhibits inter- and intra-subject variability that can be attributed to many factors including the intestinal efflux pumps such as the P-glycoprotein (P-gp). This study was done due to the great disagreement between what is published in the literature regarding the influence of P-gp on furosemide and at the same time due to the importance of this drug in the treatment of different conditions as described above. In addition, an investigation of the effect of two of the commonly used pharmaceutical excipients (hydroxypropyl β-cyclodextrin [HPβCD] and Tween 80) and also a P-gp inhibitor (verapamil hydrochloride) on the intestinal absorption of this drug were also done.

METHODS

The study utilized the everted intestinal sacs technique to investigate both the effect of the efflux transporter (P-gp) on furosemide absorption and also the effect of the chosen excipients.

RESULTS

The absorption of furosemide was significantly influenced by the P-gp as confirmed by the everted vis the non-everted sacs together with the verapamil study in which the transport of furosemide was inhibited by verapamil. In addition, Tween 80 was also shown to inhibit the P-gp pump whereas the HPβCD did not significantly influence the efflux of furosemide in this study.

CONCLUSIONS

P-glycoprotein and some of the used excipients in the formulation play a very important role in the transport of furosemide and other drugs. Thus excipients that affect the activity of P-gp should be avoided when formulating drugs that are substrate for the P-gp or other efflux pumps.

摘要

目的

呋塞米是一种常用的利尿剂,用于治疗水肿、充血性心力衰竭、高血压和肾衰竭。其吸收表现出个体间和个体内的变异性,这可归因于许多因素,包括肠外排泵如 P-糖蛋白(P-gp)。进行这项研究是因为文献中关于 P-gp 对呋塞米的影响存在很大分歧,同时也是因为这种药物在治疗上述不同疾病中的重要性。此外,还研究了两种常用药用辅料(羟丙基-β-环糊精[HPβCD]和吐温 80)和 P-gp 抑制剂(盐酸维拉帕米)对该药物肠吸收的影响。

方法

该研究利用外翻肠囊技术研究外排转运体(P-gp)对呋塞米吸收的影响以及所选辅料的影响。

结果

P-gp 明显影响了呋塞米的吸收,这一点通过外翻囊与非外翻囊的对比以及维拉帕米研究得到了证实,在维拉帕米研究中,呋塞米的转运被维拉帕米抑制。此外,吐温 80 也被证明抑制了 P-gp 泵,而 HPβCD 在本研究中对呋塞米的外排没有显著影响。

结论

P-糖蛋白和制剂中使用的一些辅料在呋塞米和其他药物的转运中起着非常重要的作用。因此,在为 P-gp 或其他外排泵的底物药物配方时,应避免使用影响 P-gp 活性的辅料。